Novartis AG (NYSE:NVS) Stock Holdings Trimmed by Visionary Horizons LLC

Visionary Horizons LLC decreased its holdings in Novartis AG (NYSE:NVS) by 2.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,080 shares of the company’s stock after selling 180 shares during the quarter. Visionary Horizons LLC’s holdings in Novartis were worth $592,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Foundations Investment Advisors LLC increased its stake in Novartis by 26.9% during the 4th quarter. Foundations Investment Advisors LLC now owns 89,074 shares of the company’s stock valued at $8,668,000 after buying an additional 18,894 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Novartis by 115.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 231,792 shares of the company’s stock valued at $26,797,000 after acquiring an additional 124,111 shares during the period. CWA Asset Management Group LLC increased its stake in shares of Novartis by 20.1% during the fourth quarter. CWA Asset Management Group LLC now owns 30,840 shares of the company’s stock valued at $3,001,000 after acquiring an additional 5,164 shares during the period. Quantbot Technologies LP raised its holdings in Novartis by 135.5% during the third quarter. Quantbot Technologies LP now owns 39,976 shares of the company’s stock worth $4,598,000 after purchasing an additional 22,998 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Novartis by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 157,256 shares of the company’s stock worth $18,088,000 after purchasing an additional 18,990 shares during the period. 13.12% of the stock is currently owned by institutional investors.

Novartis Price Performance

NVS stock opened at $106.17 on Friday. Novartis AG has a one year low of $92.35 and a one year high of $120.92. The firm has a 50-day moving average of $100.32 and a two-hundred day moving average of $108.39. The firm has a market capitalization of $217.00 billion, a PE ratio of 18.06, a P/E/G ratio of 1.70 and a beta of 0.58. The company has a current ratio of 1.04, a quick ratio of 0.90 and a debt-to-equity ratio of 0.48.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. On average, analysts forecast that Novartis AG will post 8.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NVS has been the topic of a number of research reports. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. StockNews.com upgraded shares of Novartis from a “buy” rating to a “strong-buy” rating in a research report on Saturday. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Novartis from a “hold” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, BMO Capital Markets raised their target price on shares of Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.